171 related articles for article (PubMed ID: 38175687)
61. Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness.
Huang Z; Byrd O; Tan S; Hu K; Knight B; Lo G; Taylor L; Wu Y; Berchuck A; Murphy SK
Sci Rep; 2023 Dec; 13(1):21382. PubMed ID: 38049490
[TBL] [Abstract][Full Text] [Related]
62. Targeting tumor-associated macrophages for cancer immunotherapy.
Shu Y; Cheng P
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188434. PubMed ID: 32956767
[TBL] [Abstract][Full Text] [Related]
63. Tumor-associated macrophages in immunotherapy.
Yan S; Wan G
FEBS J; 2021 Nov; 288(21):6174-6186. PubMed ID: 33492779
[TBL] [Abstract][Full Text] [Related]
64. Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy.
Xiao L; Wang Q; Peng H
Front Immunol; 2023; 14():1157291. PubMed ID: 37426676
[TBL] [Abstract][Full Text] [Related]
65. Relationship between Epithelial-to-Mesenchymal Transition and Tumor-Associated Macrophages in Colorectal Liver Metastases.
Gazzillo A; Polidoro MA; Soldani C; Franceschini B; Lleo A; Donadon M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555840
[TBL] [Abstract][Full Text] [Related]
66. Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
Kang Y; Flores L; Ngai HW; Cornejo YR; Haber T; McDonald M; Moreira DF; Gonzaga JM; Abidi W; Zhang Y; Hammad M; Kortylewski M; Aboody KS; Berlin JM
Bioconjug Chem; 2021 Aug; 32(8):1581-1592. PubMed ID: 34289694
[TBL] [Abstract][Full Text] [Related]
67. The Non-N
Xu J; Gao Z; Liu K; Fan Y; Zhang Z; Xue H; Guo X; Zhang P; Deng L; Wang S; Wang H; Wang Q; Zhao R; Li G
Front Immunol; 2021; 12():809808. PubMed ID: 35154083
[TBL] [Abstract][Full Text] [Related]
68. M2-like tumor-associated macrophages promote epithelial-mesenchymal transition through the transforming growth factor β/Smad/zinc finger e-box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamous cell carcinoma.
Sumitomo R; Menju T; Shimazu Y; Toyazaki T; Chiba N; Miyamoto H; Hirayama Y; Nishikawa S; Tanaka S; Yutaka Y; Yamada Y; Nakajima D; Ohsumi A; Hamaji M; Sato A; Yoshizawa A; Huang CL; Haga H; Date H
Cancer Sci; 2023 Dec; 114(12):4521-4534. PubMed ID: 37806311
[TBL] [Abstract][Full Text] [Related]
69. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
Zheng P; Li N; Zhan X
Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
[TBL] [Abstract][Full Text] [Related]
70. Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation.
Liu Q; Hodge J; Wang J; Wang Y; Wang L; Singh U; Li Y; Yao Y; Wang D; Ai W; Nagarkatti P; Chen H; Xu P; Murphy EA; Fan D
Theranostics; 2020; 10(18):8365-8381. PubMed ID: 32724475
[TBL] [Abstract][Full Text] [Related]
71. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
72. Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors.
Pawłowska A; Rekowska A; Kuryło W; Pańczyszyn A; Kotarski J; Wertel I
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446039
[TBL] [Abstract][Full Text] [Related]
73. CPEB3 inhibits epithelial-mesenchymal transition by disrupting the crosstalk between colorectal cancer cells and tumor-associated macrophages via IL-6R/STAT3 signaling.
Zhong Q; Fang Y; Lai Q; Wang S; He C; Li A; Liu S; Yan Q
J Exp Clin Cancer Res; 2020 Jul; 39(1):132. PubMed ID: 32653013
[TBL] [Abstract][Full Text] [Related]
74. [Effect of tumor-associated macrophages in promoting epithelial-mesenchymal transition of Hep3B hepatoma cells and related mechanisms].
Yao RR; Wang MM; Wang YH
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):305-309. PubMed ID: 29996344
[No Abstract] [Full Text] [Related]
75. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
76. The Impact of Tumor-associated Macrophages on Chemoresistance
Shibutani M; Nakao S; Maeda K; Nagahara H; Kashiwagi S; Hirakawa K; Ohira M
Anticancer Res; 2021 Sep; 41(9):4447-4453. PubMed ID: 34475068
[TBL] [Abstract][Full Text] [Related]
77. Tumor-associated macrophages promote prostate cancer progression via exosome-mediated miR-95 transfer.
Guan H; Peng R; Fang F; Mao L; Chen Z; Yang S; Dai C; Wu H; Wang C; Feng N; Xu B; Chen M
J Cell Physiol; 2020 Dec; 235(12):9729-9742. PubMed ID: 32406953
[TBL] [Abstract][Full Text] [Related]
78. Lysine demethylase 3A in hypoxic macrophages promotes ovarian cancer development through regulation of the vascular endothelial growth factor A/Akt signaling.
Song Y; Li L; Xi Y
Tissue Cell; 2023 Dec; 85():102253. PubMed ID: 37890327
[TBL] [Abstract][Full Text] [Related]
79. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling.
Huang R; Wang S; Wang N; Zheng Y; Zhou J; Yang B; Wang X; Zhang J; Guo L; Wang S; Chen Z; Wang Z; Xiang S
Cell Death Dis; 2020 Apr; 11(4):234. PubMed ID: 32300100
[TBL] [Abstract][Full Text] [Related]
80. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
